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Abstract
Advanced therapies hold substantial promise for the treatment of periodontal 
conditions. Gene therapy has the potential to transfer “therapeutic” genes, which 
express proteins such as bone morphogenetic proteins, osteoprotegerin, and tissue 
nonspecific alkaline phosphatase, which is deficient in patients with hypophospha-
tasia, a condition that affects mineralization of teeth and bone. Transferred genes 
may also express platelet-derived growth factor, which modulates the growth of 
periodontal tissue and the alveolar bone. As regards cell therapy, several clinical 
trials have shown that mesenchymal stem cells, when used with different kinds of 
scaffolds to enable the required three-dimensional environment, possess a bone 
regeneration potential that is particularly useful in such disorders as osteoporosis 
and osteonecrosis, or for regenerating alveolar bone (osseointegration) prior to 
placing a dental implant. However, much work is still required before these new 
therapies become true alternatives in routine clinical dental practice. Medical 
advances require investments, which are usually influenced by the priorities of 
both politicians and society at large. This will contribute to promoting innovation, 
efficient treatments, medium- and long-term savings, and a higher quality of life.
Keywords: Advanced therapies, gene therapy, cell therapy, tissue regeneration, 
alveolar bone, mesenchymal stem cells, biomaterials and scaffolds, implants,  
Good Manufacturing Practices, clinical dental practice
1. Introduction
Advanced therapies encompass a group of novel and innovative pharmacological 
procedures including gene therapy, cell therapy and regenerative medicine. Their 
goal is to provide curative treatment for diseases or dysfunctions that can currently 
be managed only with palliative care. According to the European Medicines Agency 
(EMA), advanced therapies are medicines for human use that are based on genes, 
tissues, or cells, offering ground-breaking new opportunities for the treatment of 
various diseases of different aetiologies, ranging from hereditary to acquired, such 
as pathogen-induced infections or cancer [1].
Gene-based medications and procedures are based on “therapeutic” genes whose 
effect may be curative, but also prophylactic or even diagnostic. By using different 
transfection methods, advanced therapies aim to insert “recombinant” genes into a 
diseased cell or organism in order to replace or repair defective genes [2, 3].
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Cell therapy procedures involve any cells that no not have the potential to 
contribute to the genetic material of the subject’s offspring (germ-line cells). After 
minimal manipulation, the cells are “implanted” “or transplanted” autologously 
(same individual), allogeneically (different individual of the same species) or xeno-
geneically (individual of a different species) into an organism in order to restore a 
diseased structure or an impaired function [4, 5].
Regenerative medicine or tissue engineering, for its part, is based on restoring 
function through the transplantation of cells, tissues, or organoids [6, 7]. Although 
regenerative medicine procedures are at the present time still at the early stages of 
development, very promising results have so far been obtained, particularly with 
regard to organoid preparation [8, 9].
For bioethical reasons, gene therapy procedures are always performed with 
somatic cells through the transfer of the “therapeutic” gene using viral or non-
viral vectors. Transfection efficacy tends to be higher with viral vectors (adeno-
associated or lentiviral viruses) but the risk of adverse events is higher, particularly 
mutagenic insertion, anaphylactic reaction, and hepatotoxic damage. Given that no 
such thing as an ideal vector exists, a compromise must be struck between sustained 
long-term expression of the transgene, which entails viral integration of the host 
cell into the genome, and a reduction in the number of adverse events [10–12].
Gene therapy procedures can be carried out in vivo through systemic perfusion 
of the gene delivery vector, or through ex-vivo vector-mediated transfection and 
subsequent reimplantation of the patient’s cells. The latter is an example of the 
administration of gene therapy followed by cell therapy.
Another more recent alternative is gene editing, which is based on the correction 
of the defective genes responsible for the patients’ symptoms. This technique uses 
tools such as Talen, zinc fingers or CRISPR/Cas9 gene editing [13].
Other kinds of gene therapy are based on siRNA, whose function is to block 
RNA translation to protein by temporarily “silencing” a specific gene [14] 
(Figure 1).
As regards the other component of these types of procedures, i.e., the target 
cells, there is a wide range of possibilities, from pluripotent cells like induced 
pluripotent stem cells (iPSCs) or embryonic stem cells (ESCs), to multipotent cells, 
mesenchymal stem cells derived from adipose tissue, bone marrow, umbilical cord, 
or dental tissue, and differentiated adult cells [15–17].
iPSCs and ESCs are pluripotent cells that must be used with great caution due to 
their teratogenicity and genetic instability [18]. Use of ESCs is moreover associated 
with important bioethical issues [19].
Mesenchymal stem cells (MSCs) are currently the only stem cells that have not 
only shown themselves to be safe in several clinical trials but have also demon-
strated their efficacy in a phase III clinical trial, which resulted in their use being 
approved by the EMA [20] for the treatment of Duchenne muscular dystrophy [21].
Although the mechanism of action of MSCs is not yet fully understood, they are 
believed to play a role in the process of tissue repair and regeneration, mainly due to 
their ability to migrate toward damaged or swollen tissues, their angiogenic capac-
ity, their anti-infectious properties and, above all, their immunomodulating and 
anti-inflammatory effect resulting from the secretion of trophic factors. Moreover, 
they are responsible for the activation of stem cells that reside in the body and for 
attracting endogenous cells to the defect site.
Although it is true that one of the most promising options arising from murine 
models was the use of preconditioned mesenchymal stem cells with different bone 
morphogenic proteins, unfortunately the in-vivo studies performed with larger 
mammals and the in-vitro studies with human mesenchymal cells yielded disap-
pointing results. This prompted the development of fresh research projects, dealing 
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particularly with the use of biomaterials to control the ability of MSCs to differenti-
ate and secrete trophic factors by generating a more favorable microenvironment. 
In the case of a large animal model, the induction of periodontal regeneration 
through the administration of locally applied growth/differentiation factors is being 
investigated in non-human primates. Dog models have been developed to study the 
application of different cells, biomaterials, and scaffolds to periodontal regenera-
tion [22]. In addition, gene therapy protocols based on the transfection of stem cells 
with viral vectors have been used in mammal models to increase the expression of 
growth factors [23].
These cells may be isolated from different tissues such as the bone marrow, 
fat, the umbilical cord, dental pulp, and more recently from endometrium and 
menstrual blood [16, 24]. They are associated with high proliferation and self-
renewal rates, they are capable of secreting countless growth factors, they are easy 
to obtain and characterize and, most importantly, they are capable of modulating 
the immune response (they have very low immunogenicity) due to the fact that they 
Figure 1. 
Application of gene- and cell therapy to bone regeneration. GMP-grade: Good manufacturing practices-grade; 
MSCs: Mesenchymal stem cells; ASCs: Adipose-derived stem cells; BMMSCs: Bone marrow mesenchymal 
stem cells; PDLSCs: Periodontal ligament stem cells; ABMSCs: Alveolar bone-derived mesenchymal stem 
cells; AAV: Adeno-associated viral vectors; LVV: Lentiviral vectors. Cell therapy is one of the techniques used 
in bone regeneration. MSCs, ASCs, BMMSCs, PDLSCs and autologous, allogenic or xenogenic ABMSCs are 
used together with scaffolds. Gene therapy procedures can be carried out in vivo through systemic perfusion 
of the gene delivery vector (AVV, LVV), or through ex-vivo vector-mediated transfection and subsequent 
reimplantation of the patient’s cells. (created in Biorender.com).
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express immunomodulating cytokines and do not express the class II major histo-
compatibility complex (MHC-II) or T-lymphocyte co-stimulating molecules such as 
CD40L, CD80 y CD86 [25].
They also display a high potential to differentiate to cells of the three germ 
layers, mesoderm (differentiation to adipocytes, chondrocytes, osteocytes, muscle 
cells and cardiac cells), endoderm (differentiation to pulmonary epithelial cells) 
and ectoderm (differentiation into neural cells). For all these reasons, MSCs hold a 
bright promise in terms of their clinical application [26, 27].
Their morphology is adherent, fibroblast-like and they express characteristic 
clusters of differentiation (CD) membrane markers such as CD44, CD90, CD117, 
CD73, CD29, CD13 and CD105. At the same time, they are negative for hemato-
poietic markers such as CD34, CD45, CD133 and BCRP1. They are endowed with a 
46X(X/Y) karyotype that is stable both timewise and in terms of culture passages 
as it is able to maintain telomerase activity until passage 10. This turns MSCs into a 
useful cell therapy vehicle as they are exempt from genetic variability and tumori-
genesis. They also express embryonic transcription factors such as Oct-4, Rex1 and 
GATA-4, but not embryonic stem cell markers such as SSEA-1, SSEA-4, TRA-1-60 
and TRA-1-81 [28].
Despite the vast amounts of data available on mesenchymal stromal cells and on 
the different protocols developed for their expansion, characterization and differ-
entiation, as well as for their manufacturing, good manufacturing practice (GMP) 
protocols for the process extending from the validation of MSCs to their preparation 
for clinical use, are still in their infancy [29].
The EMA has since 2007 considered expanded MSCs to be advanced therapy 
medicinal products (ATMPs) fit for clinical use [1].
Although different GMP protocols have been established concerning the isola-
tion and expansion of MSCs, there is still little understanding of the soundness of 
the required preclinical protocols and their translation to research programs. In 
this regard, the International Society for Cellular Therapy (ISCT) has established 
a series of minimum criteria to define the identity and quality of these cells before 
they can be categorized as ATMPs [30–33]. Although there is some flexibility 
depending on the types of clinical trials and the regulations issued by different 
governments, ISCT’s fundamental criteria are related with microbiological assays, 
endotoxin and mycoplasma testing, feasibility tests, clonogenicity, and purity and 
functionality analyses.
The criteria generally used to validate the use of MSCs in clinical practice are 
related with the following: manufacturing approval by an ethics committee and 
participation of authorized sites; donor selection; isolation and expansion of the 
cells in accordance with GMPs [clonogenicity tests (fibroblast colony-forming 
units); flow immunocytometry-based cell characterization; differentiation poten-
tial assays]; quality control (microbial testing, mycoplasma and endotoxin detec-
tion, karyotyping); and shipment from the manufacturing site to the clinical site 
where they are due to be used in the conditions required for this ATMP (tempera-
ture between 3 and 5°C and delivery time under 24 hours) [29].
2. Gene therapy in periodontal disease
As explained above, and as will be specified below, cell therapy is at present the 
most potentially useful tool to treat periodontal disease. However, gene therapy 
protocols can also make important contributions in specific cases.
Gene therapy may allow an increase in the bioavailability of certain growth 
factors or even some proteins that contribute to promoting the modulation of 
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periodontal tissue, specifically alveolar bone. The cells in the periodontal ligament 
(PDL) are thus characterized by several protein markers such as type III collagen, 
osteopontin, bone morphogenetic proteins (BMPs), osteocalcin and bone sialo-
protein. Among them, BMP-4 is particularly important for bone growth and bone 
remodeling as it stimulates the expression of osteopontin, BMP-2 and the mRNA of 
osteoblast-specific transcription factor CBFA1 in human PDL cells. In this respect, 
Tsuchiya et al. [34] used a (highly safe) non-viral electroporation-based plasmid 
delivery technique to overexpress BMP-4. In vitro transfected rat PDL cells exhib-
ited production and secretion of the mature form of BMP-4 without any cases of 
inflammation, degeneration, or necrosis.
Also, ex-vivo gene therapy experiments have studied the transfer of the BMP-2 
gene using bone marrow-derived mesenchymal stromal cells (BMMSCs), muscle-
derived cells, adipose-derived stem cells (ASCs), periodontal ligament stem cells, 
and fibroblasts, also showing an increase in osteogenic differentiation and mineral-
ization [35].
Another interesting approach that used the same protocols consisted in the in 
vivo transfer of the gene that consistently expresses platelet-derived growth factor 
PDGF-B locally in the alveolar bone, which has been shown to stimulate the regen-
eration of the periodontal tissue in bone defects in rat models [36]. Periodontal 
lesions have been treated with a matrix containing adenovirus as a transfer vector 
expressing PDGF-B. Results showed higher levels of proliferating cell nuclear anti-
gen, with positive cell staining and strong evidence of bone and cementum regen-
eration. A quantitative analysis showed a nearly four-fold increase in the volume of 
the alveolar bone and a six-fold increase in the rate of cementum repair in the areas 
treated with the vector.
Studies on the use of gene therapy to overexpress some proteins related to 
bone resorption such as osteoprotegerin [37] have shown that these proteins could 
constitute potential alternatives for modulating and regulating bone mass in cases 
of bone weakness; alveolar, mandibular, or maxillary bone osteoporosis; or where 
the alveolar bone needs to be bolstered prior to tooth implantation. Osteoprotegerin 
is a protein secreted by osteoblasts and stromal osteogenic stem cells that bears close 
resemblance with other members of the tumor necrosis factor family. It acts as a 
decoy receptor for receptor activator nuclear factor kappa-B (RANKL) and indi-
rectly inhibits osteoclast differentiation and activation, reducing bone resorption.
In a rat model of periodontitis-derived alveolar bone resorption, non-viral gene 
therapy-based transfection using a subperiosteally injected osteoprotegerin gene-
expressing plasmid achieved a significant reduction in alveolar bone resorption and 
an increase in the number of active osteoclasts [37].
More recently, gene therapy protocols are successfully being used to study other 
disorders that would not at first sight seem to be amenable to these techniques, such 
as hypophosphatasia.
Hypophosphatasia (HPP) is an uncommon hereditary disorder that affects 
mainly the mineralization of bones and teeth. HPP is caused by loss of function 
mutations (up to 388 have been reported) in the ALPL gene (chromosome 1) that 
expresses tissue-nonspecific alkaline phosphatase (TNALP) [38].
Insufficient levels of TNALP, an enzyme found mainly in bone, liver, and renal 
cells, result in elevated extracellular concentrations of inorganic pyrophosphate 
(PPi), pyridoxal 5′-phosphate (PLP), and phosphoethanolamine (PEA). The ensu-
ing increase in the extracellular PPi/inorganic phosphate (Pi) relation acts as an 
inhibitor of bone mineralization, affecting mainly the hard dental tissue (alveolar 
bone) and resulting in premature tooth loss [39–41].
In general, justification for research into and subsequent application of new 
advanced therapies depends on the availability (or lack thereof) of an appropriate, 
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convenient, and safe treatment for a given condition. In the case of HPP, treatment 
before 2015 consisted in an attempt to mitigate symptoms by controlling calcium 
and phosphorus levels. Enzyme replacement therapy with asfotase alfa has gained 
popularity in recent years [42], although the treatment is not always effective.
As regards the new advanced therapies, the first few clinical applications 
corresponded to cell therapy protocols. In this respect, Cahill et al. [43] were able 
to correct a severe HPP phenotype by transplanting osteoblasts with high levels of 
TNALP. Migration of these osteoprogenitors to the affected areas of the bone was 
successful in converting the disease phenotype from severe to mild.
Cell therapy protocols often produce low levels of the deficient protein and, 
moreover, such production is systemic. For this reason, it is in many cases inevitable 
to resort to gene therapy protocols which, apart from allowing higher therapeutic 
efficacy, exhibit longer-term sustained expression levels. Furthermore, they can be 
applied locally, e.g., in the periodontal tissue. In this regard, Okawa et al., [44] in 
an ex-vivo gene therapy experiment whereby lentiviral vectors and BMMSCs were 
used with TNALP-deficient knockout mice, were able to induce alveolar bone and 
cementum formation in those mice, significantly in the first case and moderately in 
the second, thus contributing to inhibiting premature tooth exfoliation.
More recent gene therapy studies using adeno-associated vectors have shown 
greater promise. Following administration of the TNALP-expressing adeno-
associated vector scAAV8-TNALP to TNALP-deficient knockout mice, Ikeue et al. 
[45], were successful in achieving enhanced growth of the mandible, the alveolar 
bone, and the molar roots, inducing dentoalveolar mineralization and reducing 
the exfoliation risk. The same authors have optimized the efficacy of the technique 
thereby facilitating its translation to clinical practice [46].
3. Cell therapy and the regeneration of alveolar bone
The periodontium is a complex organ made up of four mesenchymal compo-
nents (gingiva, cementum, alveolar bone and the PDL), which constitute a func-
tional unit in charge mainly of anchoring the tooth to the jawbone firmly enough 
to withstand the masticatory forces, and of regulating homeostasis within the oral 
cavity [47, 48].
The PDL plays a fundamental structural role as it connects the cementum to the 
alveolar bone. It is a highly vascularized cellular tissue (fibroblasts and endothelial, 
epithelial, neural, and undifferentiated mesenchymal cells), made up of thick 
collagen fibers that are inserted into the external layers of the cementum and of 
the alveolar bone. Dental tissue-derived mesenchymal stem cells are responsible 
for maintaining hemostasis across all periodontal tissues as they are capable of 
differentiating to cementoblasts, which give rise to the deposition of cementum; 
to osteoblasts, which give rise to the deposition of bone; and to fibroblasts, which 
foster the formation of new connective tissue [47] (Figure 2).
Maintenance and regeneration of alveolar bone and of tooth and implant-sup-
porting structures are based on a balance between bone resorption and bone forma-
tion [49], which is controlled by different types of cells, signaling mechanisms, and 
matrix interactions. Advanced therapies, particularly cell therapy and regenerative 
medicine, could be considered potential tools capable of restoring that balance in 
soft and hard tissues, making it possible to treat traumatic, metabolic, or congenital 
disorders that affect periodontal tissue regeneration [50].
This chapter will succinctly cover the possibilities offered by cell therapy for 
the treatment of disorders related to the loss and defective regeneration of bone 
mass such as osteoporosis or osteonecrosis (the former understood as a systemic 
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metabolic disease of bone and the latter as an apoptotic loss of bone mass, particu-
larly from the alveolar sockets), and for regenerating bone prior to placing a dental 
implant (osseointegration) [51].
The first pioneering studies on the regeneration of alveolar bone using cell 
therapy were conducted by Abukawa et al. in 2003 [52]. These authors used porcine 
MSCs isolated from the bone marrow, which were differentiated to osteoblasts and 
then incorporated to and cultured on a porous scaffold made from biodegradable 
poly DL-lactic co-glycolic acid. The result was the formation of bone on the scaf-
fold’s surface.
In 2004, the same authors [53] confirmed their results in vivo in a porcine model 
by using autologous constructs (cell-seeded scaffolds) to reconstruct the segmented 
mandible of the induced model. This resulted in the regeneration of the damaged 
areas of the mandible, which, in clinical, radiographic, and histologic studies, were 
found to contain osteoblasts, osteocytes, bone trabeculae and blood vessels.
Some time later, Streckbein et al. [54] marked a turning point in the application of 
cell therapy to periodontal disease. Indeed, human ASCs became a powerful cell ther-
apy tool. ASCs were found to resemble BMMSCs in their capability of differentiating to 
osteocytes. Engraftment of autologous ACSs in a fibrin scaffold in a rat model resulted 
in the formation of significantly greater amounts of bone than in the control group.
3.1 Osteoporosis
Osteoporosis is a chronic (long-term) skeletal condition typically caused by an 
alteration in bone homeostasis arising from an imbalance between bone resorption 
and bone formation. Osteoporosis is responsible for the majority of fractures in 
the elderly and in post-menopausal women, who tend to experience a reduction in 
Figure 2. 
Periodontium and PDL cells. The periodontium is made up of four mesenchymal components (gingiva, 
cementum, alveolar bone and the PDL). The PDL, which connects cementum to alveolar bone, is formed by 
fibroblast, epithelial cells, endothelial cells, neural cells and mesenchymal stem cells. Mesenchymal stem cells 
are responsible for maintaining bone hemostasis by differentiation to cementoblast, osteoblast and fibroblast. 
(created in Biorender.com).
Human Teeth – Structure and Composition of Dental Hard Tissues and Developmental…
8
bone mass and bone density. Although a genetic predisposition is undeniable, other 
causative factors such as the slower development of bone mass during youth as well 
as ethnicity, sex, lifestyle and iatrogenesis usually play a role [55, 56].
Osteoporosis is one of the main causes of alveolar, mandibular, and maxillary 
bone fractures as these bones are constantly subject to movements and strong 
masticatory forces, with the mandibular bone withstanding the greatest mastica-
tory forces and exhibiting the most trabecular structure. It is the dentist’s job to 
diagnose potential cases of osteoporosis as early as possible, particularly with a view 
to evaluating the need of implants. Current treatment for osteoporosis disorder 
is based on antiresorptive and anabolic drugs (oestrogens, bisphosphonates and 
monoclonal antibodies such as RANKL inhibitors [55].
What contribution can cell therapy make to the future treatment of this disor-
der? Simply put, cell therapy can offer “curative” rather than palliative treatment, 
restoring the structure and function of bone tissue. MSCs are the best candidates on 
account of their anti-inflammatory and immunologic characteristics, and of their 
widespread bioethical acceptance [57].
It has been suggested [58] that one of the factors leading to osteoporosis in aged 
bone tissue is the reduction in the number of MSCs in the bone and the resulting 
lower osteoblastic differentiation potential. According to several studies, this is 
where cell therapy would play its most evident clinical role [59–61].
The kind of osteoporosis brought about by post-menopausal estrogen deficiency 
exhibits very high mortality rates with an associated risk of fracture and of tooth 
and alveolar bone loss from the jaw. In a study aimed at evaluating the previ-
ously stated premise [58] that aging of BMMSCs contributes to the development 
of osteoporosis, Xu et al. [62] analyzed the effect of special AT-rich sequence-
binding protein 2 (SATB2), a regulator of stemness and senescence of craniofacial 
bone-marrow derived mesenchymal stem cells, on ovariectomy-induced alveolar 
osteoporosis in a rat model. Transplantation of BMMSCs transfected with the 
SATB2-expressing gene ameliorated the disease phenotype, reducing cell senes-
cence, increasing stemness and osteogenic capacity, and diminishing the number of 
osteoclastic markers present as well as the adipogenic potential of the cells and the 
in vivo ovariectomy-induced loss of alveolar bone.
3.2 Osteonecrosis
Osteonecrosis is a clinical entity characterized by apoptosis of the cells that make 
up the bone and the bone marrow. It is usually associated with the appearance of 
necrotic areas in the trabecular bone, the subchondral bone, and the bone marrow 
and, although it could affect any bone, it is most frequently found in the jawbone 
or, more specifically, the maxilla. Jaw osteonecrosis is an infrequent yet serious 
condition that involves the maxillary bone [63].
Osteonecrosis generally sets in as a result of exposure of the jawbone to the oral 
cavity for a period of at least 8 weeks, following which cells (usually osteocytes) 
become senescent and apoptotic from lack of blood supply from the gingiva. 
Although there is still no consensus regarding the osteopathogenesis of osteone-
crosis, certain situations have been identified as potential causative mechanisms: 
invasive dental procedures such as tooth extraction surgery; trauma in the area of 
the maxillary; abnormal (spontaneous) growth of the bone in the palatal area or 
the internal areas of the mouth, even in patients without identifiable risk factors; 
radiation therapy (radiation-induced osteonecrosis); head and neck cancer; herpes 
zoster virus infection; steroid treatments; osteomyelitis; and chronic bone infec-
tion. Jaw osteonecrosis may remain asymptomatic for long periods of time, typical 
symptoms including pain in the affected area, inflammation episodes, redness, 
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and other signs of infection in the gingiva. Patients may experience numbness or a 
feeling of heaviness in the jaw, develop a purulent secretion in the area of exposed 
bone, exhibit intra- or extraoral fistulas, or suffer the loosening and loss of the 
teeth close to the affected area as a result of the weakening of the bone that anchors 
the teeth [64, 65].
As far as diagnosis is concerned, there is at present no predictive diagnostic 
test capable of determining if a patient is at risk of or predisposed to suffering jaw 
osteonecrosis. A number of salivary biomarkers have recently been described, 
which may potentially help in diagnosing and monitoring the most common oral 
conditions, including oral leukoplakia, oral lichen planus, Sjögren’s syndrome, 
periodontitis, peri-implantitis, and medication-related osteonecrosis of the jaw 
[66]. Salivary biomarkers such as interleukins or growth factors have shown them-
selves useful in diagnosing and following up these conditions, making it possible to 
conduct an early evaluation of the risk of malignization and monitor the efficacy of 
treatment.
Treatments based on antiresorptive drugs such as bisphosphonates adminis-
tered to patients at high risk of osteoporosis or as treatment for bone cancer have 
often resulted in an increase in jaw osteonecrosis [67, 68]. The mechanism by 
which bisphosphonates may result in maxillary osteonecrosis are currently not 
understood, but they have been shown to affect dentoalveolar structures, limiting 
or impeding bone regeneration due to inhibition of osteoclast formation and/or 
suppression of cell turnover.
Prevention through health education, dental hygiene and periodic dental visits 
from early childhood is essential. In most cases, a detailed anamnesis is crucial for 
both early detection and prevention [69–71]. Routine treatment is based on antibiot-
ics, antibacterial mouthwashes such chlorhexidine, and removable oral appliances 
(retainers) or dental debridement.
There being currently no standard treatment to promote regeneration of the 
necrotized area, advanced therapies and, specifically cell therapy, are emerging as 
valuable tools not only to curb the necrosis but also to restore and regenerate the 
necrotized areas. Although studies have so far focused on bisphosphonate-induced 
jaw osteonecrosis, the solutions they propose – if effective – could be applied to 
most kinds of jaw osteonecrosis, regardless of their etiopathogenesis.
The first clinical trial that used cell therapy to attempt regeneration of the 
alveolar maxillary bone was conducted in 2009 by d’Aquino et al. [72]. The authors 
used a biocomplex consisting of autologous dental pulp stem cells and a collagen 
scaffold. Histological observation unambiguously showed complete regeneration of 
the bone at the necrotic site with optimal rehabilitation of the alveolar bone and full 
restoration of the periodontal tissue.
Very good alveolar bone regeneration results have also been obtained in 
bisphosphonate-induced osteonecrosis models using allogeneic bone marrow 
[73] or ASCs [74]. The advantage of ASCs, as compared to BMMSCs, lies in their 
easy and less invasive harvest, their higher yield, their higher proliferation and 
duplication potential, their lower levels of senescence; and their higher angiogenic 
anti-inflammatory capacity. These cells also exhibit higher survival rates in isch-
emic environments as well as an increased secretion of growth factors such as the 
vascular endothelial growth factor (VEGF), hepatocyte growth factor (HGF), and 
basic fibroblast growth factor (bFGF). These factors are required in hypoxic envi-
ronments, which is useful for the treatment of osteonecrosis and bisphosphonate-
related ischemic wounds derived from jaw osteonecrosis [74, 75].
There is currently only one clinical trial underway aimed at evaluating the use 
of cell therapy for the treatment of jaw osteonecrosis [76]. It specifically seeks to 
determine the safety of using autologous BMMSCs in the presence of a porous 
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tricalcium phosphate scaffold and in a demineralized bone matrix in patients 
with jaw osteonecrosis. It is a phase I, prospective non-randomized single-centre 
unblinded open clinical trial including patients between 18 and 85 years of age. 
The study is the result of a collaborative effort between the Virgen de la Arrixaca 
Institute of BioHealth Research (Region of Murcia), the Virgen de la Arrixaca 
University Hospital (Region of Murcia), the Regional Ministry of Health of Murcia 
and the Spanish Ministry of Health.
Patients with a definitive clinical and radiological diagnosis of jaw osteonecrosis, 
of whatever etiology, are implanted with the cell “construct” (MSCs, tricalcium 
phosphate and demineralized bone matrix). One month prior to implantation, 
the MSCs are first harvested from the patients’ bone marrow and then character-
ized and expanded in GMP-grade conditions. The cells are seeded in tricalcium 
phosphate and maintained in culture for 14 days. On the day of implantation, the 
MSCs seeded in tricalcium phosphate are admixed with the demineralized bone 
matrix, the combination being subsequently coagulated with autologous platelet-
rich plasma before engraftment can occur. Finally, the oral mucosa or the skin are 
closed tightly with silk sutures. A careful evaluation must be made of different 
circumstances related with the procedure such as bone ischemia or new bone for-
mation; non-severe adverse events related with the procedure such as local surgical 
wound infections, non-union and anaphylactic reactions; time to wound healing; 
appearance of local pain as determined by a visual analogue scale; bone forma-
tion as measured by computerized tomography; and quality of life as measured by 
EuroQol-5D [77, 78].
Mesenchymal stem cells could also play an important osteogenesis and bone 
regeneration role in cases of osteoradionecrosis [79], a severe and difficult-to-
manage complication of the jawbone following high-dose radiation therapy in cases 
of head and neck cancer.
3.3 Bone regeneration and osseointegration prior to dental implant placement
Placement of intraosseous implants is a routine dental procedure aimed at 
restoring missing teeth and masticatory function. However, the stability of 
implants is often compromised by the presence of an insufficient amount of sup-
porting bone mass. Sinus elevation treatment using autologous bone and allografts 
is the standard alternative in these cases. The problem lies in amount of autologous 
bone required for such procedures, which varies as a function of the magnitude of 
the damage present. Moreover, alternative alloplastic materials are often ill suited to 
compromised vascular environments.
Initial studies in this field, such as those by Matsuo et al. [80] have made inter-
esting contributions. Using particulate cellular bone and marrow (PCBM) and 
platelet-rich plasma (PRP), these authors obtained statistically significant increases 
in the volume of trabecular bone. Equally interesting findings were reported by 
Trautvetter et al. [81] who evaluated the effect of applying autologous periosteal 
bone grafts in conjunction with scaffolds to atrophic maxillary bone on long-term 
clinical restoration in one-stage procedures, which also involved placement of 
dental implants. At six months post-op, these authors observed the presence of 
trabecular bone with active osteocytes and osteoblasts and no signs of bone resorp-
tion, connective tissue formation or necrosis.
Different alternatives have been tested, with varying degrees of success in an 
attempt to achieve bone regeneration, including multiple biomaterials and scaf-
folds (both natural and artificial), different types of stem cells obtained from the 
dental follicle, the periodontal ligament, the dental pulp, the salivary glands and 
the adipose tissue; and the multiple growth factors used for dentistry applications 
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in the framework of tissue engineering programs. Nonetheless, developing new 
methodologies and strategies is required to address the problems inherent in the 
reconstruction of periodontal bones and tissues [82].
Further in-depth research will be required to determine the influence of the 
microenvironment inside the damaged periodontium on the efficacy of the new 
strategies that are being developed [83]. The microenvironment exerts a very 
significant influence on physiological and physiopathological function, and on 
the therapeutic effect of MSCs. The niche where these cells reside is made up of 
multiple cell populations, tissue components, and soluble factors that regulate the 
cells’ behavior. The fact that viability and differentiation of MSCs are compromised 
in conditions such as osteoporosis and periodontitis may aggravate the patient’s 
condition and disrupt the tissue healing process.
Studies are currently underway to investigate ways of improving and optimizing 
the microenvironment where transplanted cells are going to reside. These stud-
ies have used either pharmacological or epigenetic techniques [84], or cell-free 
(extracellular vesicle-based) applications [85] to enhance the resistance of exog-
enous MSCs.
In any event, whether by classical methods or by cell therapy protocols, all 
efforts should be aimed at achieving osseointegration to enhance implant efficiency 
and durability [86]. The key milestones on the road to osseointegration are as fol-
lows: firstly, it is essential to make sure that periodontal tissue responds positively 
to the implant from the outset; subsequently, it must induce osteogenesis and bone 
remodeling around the implant. As osseointegration is a process mediated by the 
innate immune system that involves the complement system and reactive macro-
phages, factors such as the design and the chemical composition of the implant, the 
surgical technique employed, the use of “therapeutic cells”, the local microenviron-
ment and the patient’s systemic characteristics, may play a significant role.
Recourse to StemBios Cell therapy has facilitated induction of early osseo-
integration in primary dental implants. StemBios Cells® are pluripotent stem 
cells derived from adult blood and bone marrow. They are equipped with specific 
biomarkers and can be easily cultured in vitro in large quantities. They possess the 
advantages of embryonic stem cells but, unlike them, they are not teratogenic, and 
they cannot result in immunologic rejection. They are capable of differentiating 
to endodermal, mesodermal and ectodermal cells, both in vivo and in vitro. In an 
analysis of 11 subjects who had received a dental implant in the mandible only one 
of whom was treated with StemBios cell therapy at the time of implantation, Weng 
et al. [87] found that this subject exhibited superior healing of the bone tissue, par-
ticularly regarding early bone ingrowth, as compared with that observed following 
implantation without this kind of cell therapy.
More recently [88] it has been shown that BMMSCs play an important role in 
the efficacy and induction of osseointegration following dental implant placement. 
Uncontrolled diabetes mellitus is known to result in very poor osseointegration and 
reduced implant durability. Alqahtani et al. analyzed the effect of BMMSCs in the 
presence of platelet-rich plasma on the osseointegration of implants placed in New 
Zealand rabbits with induced type 1 diabetes. Implants were placed with the help 
of collagen sponges loaded with osteoinductive BMMSCs and platelet-rich plasma. 
Osseointegration was significantly more effective in the presence of BMMSCs than 
in implantations where only platelet-rich plasma was used.
As other tissues in the human body, periodontal tissues are endowed with a res-
ervoir of MSCs that share the same characteristics as other mesenchymal cells such 
as adherence, the potential to differentiate to at least three cell lines, and specific 
cluster of differentiation markers for stromal cells [89]. In addition, these cells 
possess immunomodulating functions. Their properties make these cells potentially 
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applicable in clinical practice for the treatment of periodontal and other conditions, 
even neurodegenerative ones, such as Parkinson’s disease [90].
The first mesenchymal cells isolated from periodontal tissues were human dental 
pulp stem cells (hDPSCs), followed by apical papilla stem cells (SCAPs), periodontal 
ligament stem cells (PDLSCs), gingiva-derived mesenchymal stem cells (GMSCs), 
dental follicle stem cells (DFSCs), tooth germ stem cells (TGSCs), and alveolar 
bone-derived mesenchymal stem cells (ABMSCs). PDLSCs, GMSCs, TGSCs, SCAPs 
and ABMSCs, the latter sharing many characteristics with BMMSCs, present osteo-
genic capacity. For their part, DFSCs play a role in the formation of alveolar bone 
and the root-bone interface in tooth development [89].
Unfortunately, the number of stromal cells that can be obtained from periodon-
tal tissue is extremely low, which represents a significant hurdle for the use of those 
cells when harvested autologously (directly from the patient). This makes it neces-
sary to use other allogeneic sources of adult tissue such as BMMSCs and, especially, 
ASCs, given their greater ease of harvest and greater yield [91].
As a general concept cell therapy, as used to regenerate periodontal bone tis-
sue, is based on a combination of a cellular element, made up of the patient’s own 
autologous mesenchymal stem cells, an extracellular element, or scaffold, that 
provides a substrate for tissue growth and, lastly, a series of chemical-molecular ele-
ments, mainly trophic and growth factors secreted by the cells themselves, that play 
a role in the regenerative process. In other words, cell therapy involves an osteogenic 
cellular component, a series of osteoconductive signals (trophic factors) and an 
osteoconductive support component (scaffold). In this regard, given that there are 
multiple factors that may have an impact on the success of these new therapies, the 
results of translating the findings of preclinical trials using in vivo animal models to 
the human clinical setting, are not always the ones initially expected. The reasons 
for this discrepancy are basically related with size-related differences between 
human and animal defects and with what is known as “diffusion distances,” which 
have to do with limitations to massive transport (e.g., oxygen diffusion and elimina-
tion of metabolic waste), which are essential for the survival of the transplanted 
cells. Moreover, as mentioned above, there may exist significant differences 
between animal and human models in terms of the local microenvironment where 
the cells reside, and in terms of the epigenetic processes at work in each of them. 
These aspects are likely to exert a huge impact on the results obtained [83, 84]. For 
these reasons, hystomorphometric analysis of biopsy samples is the most effective 
way of quantitatively evaluating regeneration of the bone structure [92].
It should be noted that, when applying advanced therapies (MSC-based 
therapy), apart from measuring the efficacy of the procedure, it is essential to 
consider its cost-effectiveness. Although the cost involved in the expansion and 
preparation of cells is high in GMP-grade procedures [29], several studies [93] have 
confirmed that, taking into account the indirect costs related to hospitalization and 
complementary treatments such as general anesthesia and the higher complications 
rate and higher morbidity associated with traditional grafting procedures, the cost-
efficiency of the new advanced therapies could be higher.
3.4 Clinical trials in progress
As mentioned above in this chapter, although we have a robust understanding of 
the properties of stem cells and of the viral vectors used for gene transfer, there still 
remains work to be done before they can be applied to clinical practice, including 
GMP protocols [29]. The gap will be bridged gradually as the results of the different 
clinical trials underway on the new or advanced therapies become available. The 
ISCT has already established a series of minimal safety requirements that must be 
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met when defining the identity and quality of these cells as ATMPs. These require-
ments are mainly related with the risk of contamination by pathogens, the presence 
of endotoxins and mycoplasma, the viability of the cells, the safety of the viral 
vectors and the teratogenic safety of the cells. These requirements must unfailingly 
be met by any clinical study that is undertaken.
One of the first successful clinical trials that used BMMSCs was performed by 
Gjerde et al. (ClinicalTrials.gov identifier: NCT02751125) [94, 95], which started 
enrolling patients in April 2016 and was concluded in March 2020. The trial was 
sponsored by the University of Bergen with the collaboration of Ulm University, 
Haukeland University Hospital, University of Nantes, Madrid’s Complutense 
University, the University of Aarhus, the International University of Catalonia, 
Assistance Publique - Hôpitaux de Paris and the European Commission. It was a 
pilot project aimed at reconstructing atrophied posterior mandibular alveolar ridges 
by using biomaterials and autologous BMMSCs. The last step in the process was 
the insertion of an implant into the newly formed bone. This was an interventional 
clinical trial with 13 subjects, between 18 and 80 years (Figure 3).
Cells were obtained from the bone marrow of the patients’ alveolar ridge. The 
sample was processed in a cell therapy lab using GMP-grade protocols. Cells were 
expanded and characterized through flow immunocytometry and, 21 days later, 
they were transplanted to the subjects’ alveolar bone. Before closing the transplant 
site, the cells were brought into contact with dicalcium phosphate (DCP) and 
the material was covered with a reinforced titanium membrane. From four to 
six months later, the bone was biopsied and implants placed in the regenerated 
bone. Patients were followed up for 1, 2, 3 and 5 years to assess the stability of 
the implant. Moreover, the newly formed bone was clinically and radiologically 
assessed. Implant stability was measured using the Ostell™ system, based on 
Resonance Frequency Analysis (RFA) [96]. In addition, an evaluation was made of 
potential adverse events derived from the treatment in general and of the cells in 
particular (safety and tolerability).
Results showed that clinical reconstruction of the alveolar ridge is a feasible and 
safe procedure yielding a predictable outcome. Osseointegration was achieved in all 
dental implants.
A promising clinical trial (ClinicalTrials.gov identifier: NCT04297813) got 
underway in March 2020. It is meant to be the first controlled trial using autologous 
mesenchymal stem cells, cultured, expanded, and maintained using synthetic 
biomaterials with the aim of regenerating enough maxillary bone to offer support 
to dental implants. The coordinators of the study are Pierre Layrolle, from the 
University of Nantes (France) and Kamal Mustafa, from the University of Bergen 
(Norway) and it is sponsored by the European Union (H2020 Maxibone Project). 
This clinical trial follows on from a previous study by Gjerde et al. [94, 95].
It is a phase III interventional multicentre randomized controlled clinical trial of 
150 patients over 18 years of age. It is aimed at comparing the safety and efficacy of 
using autologous mesenchymal stem cells cultured on calcium phosphate biomate-
rials against the use of autologous bone grafts. Patients have been randomized into 
either a control group, where subjects receive standard treatment (a jawbone graft), 
or an experimental group, where subjects receive a combination of biomaterials and 
cultured and expanded autologous stem cells [97].
The cells are obtained from the patients’ coxal bone marrow. These stem cells 
are being expanded and produced in two different labs, one at the Transfusional 
and Immunogenetic Medicine Institute of the University of Ulm (Germany), and 
the other at the Créteil Centre de Thérapie Cellulaire (France). After two weeks, 
the mesenchymal stem cells are sent to a surgical clinical centre where they are 
brought into contact with a biomaterial (DCP) and, subsequently, engrafted onto 
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the maxillary and mandibular alveolar ridges. Patients in the control group are 
engrafted with autologous bone from the posterior mandibular ramus. A non-
resorbable membrane is used to cover the grafts and guide the tissue regeneration 
process. Five months later, the implants are placed following an assessment of the 
amount of bone regeneration obtained. Bone biopsies are then obtained, which 
are evaluated by synchrotron, microcomputerised tomography and histology. 
Subsequently, once dental implants have become osteointegrated, the protective 
elements can be placed.
The primary outcome measure in this study will be an evaluation of the changes 
in the linear measurements of the alveolar bone width, as measured below the 
alveolar ridge immediately before placement of the implant. Secondary outcome 
measures will consist, on the one hand, in a VAS evaluation of postoperative pain 
following each of the two treatments [98] and, on the other, of radiological analy-
ses to determine the bone volume present, thus gauging the amount of new bone 
obtained. This will allow making an informed decision regarding the possibility of 
Figure 3. 
Clinical trials currently in progress. GMP-grade: good manufacturing practices-grade; BMMSCs: bone marrow 
mesenchymal stem cells; DCP: dicalcium phosphate; VAS: visual analog scale; CBCT: cone beam computed 
tomography; RFA: resonance frequency analysis. These clinical trials are based on the use of BMMSCs 
together with dicalcium phosphate (DCP). The objective was to reconstruct atrophied posterior mandibular 
alveolar ridges by using biomaterials and autologous BMMSCs. The last step in the process was the insertion 
of an implant into the newly formed bone. Patients were followed clinically and radiologically. (Created in 
Biorender.com).
15
Gene and Cell Therapy in Dental Tissue Regeneration
DOI: http://dx.doi.org/10.5772/intechopen.97757
placing an implant in the reconstructed area. Such as decision will be made on the 
basis of 3D Cone Beam Computed Tomography (CBCT) [99].
To be included in the trial subjects have to be healthy, non-smokers and in need 
of implants in the upper or lower jaw, with loss of vertical height and less than 4 mm 
lateral width. Exclusion criteria include the general contraindications for dental 
and/or surgical treatment, and for harvesting bone marrow specimens or bone 
grafts; a history of any malignant disease; previous or concurrent radiation therapy 
of the head and neck; a history of infectious diseases (HIV, syphilis, hepatitis B or 
C); uncontrolled diabetes mellitus; inflammatory or autoimmune diseases of the 
oral cavity; and previous or concurrent immunosuppressive treatment or high-dose 
bisphosphonate or corticosteroid therapy.
4. Reflections on the application of advanced therapies in dentistry
Advanced therapies encompass a wide-ranging series of different therapeutic 
procedures that can be applied to most conditions, transmissible or otherwise 
[100]. They are multidisciplinary procedures that may involve basic molecular and 
cellular biology techniques and tissue engineering [101]. In general, implementa-
tion of a new healthcare technology, understood in this case as a new therapeutic 
procedure, has vast repercussions not only from the clinical point of view but also 
from a social and economic perspective. This places a heavy responsibility on the 
shoulders of managers and officials in charge of its application. To this should be 
added human innate reluctance to adopt new ideas especially when, as in the case 
of the new therapies, there are so many unknowns regarding potential medium 
and long-term effects. However, some clinical disciplines are more open to change 
than others. This should be considered together with the social, legal and bioethical 
considerations associated to the introduction of any new technology [102–104].
An explanation must be found to the fact that despite the significant progress 
made and the success obtained by research into ATMPs in the last few years, the 
number of procedures and products authorized by evaluation agencies has been 
extremely low and limited to relatively severe conditions. Going back to dentistry, 
although significant improvements have been made on the more classical techniques 
and on advanced therapies, much work remains to be done before many of these 
procedures become standard clinical practice. The reasons for this may be related to 
the novelty of the techniques themselves or to other factors of a social, economic, or 
bioethical-legal nature, without mentioning the inherent distrust of practitioners 
and the general public toward these innovative procedures. Indeed, even if dental 
conditions are not in principle potentially fatal and may often be prevented, they 
are highly prevalent, affecting more than 3,5 billion people worldwide [105]. They 
are therefore associated with a high economic cost and, very often, a low quality 
of life. They are also a social problem as they typically affect the less affluent social 
classes [106]. Moreover, dental infections could result in a worsening of systemic 
conditions, such as cardiovascular disease [107, 108]. For all these reasons, any 
procedure that may ensure greater medium- and long-term efficacy of dental proce-
dures should be eagerly embraced.
What could then be the reasons behind the low number of patients enrolled 
in advanced therapy programs in routine periodontal practice? The first explana-
tion, applicable to any type of condition except severe or fatal ones, is the lack of a 
sufficient number of preclinical and clinical trials to confirm the therapy’s efficacy 
and, particularly, its safety. As advanced therapy procedures were introduced only 
recently, their potential, especially long-term, adverse events are not known. It is 
therefore essential for a whole body of new clinical trials to be undertaken to dispel 
Human Teeth – Structure and Composition of Dental Hard Tissues and Developmental…
16
misgivings and promote confidence among patients. This will inevitably require 
greater economic investments in research.
As far as the safety of these protocols is concerned, the more stringent require-
ments imposed by regulatory agencies typically results in a delay in the imple-
mentation of these new therapies. In this regard, special programmes have been 
introduced in the last few years to accelerate regulatory procedures and overcome 
the so-called “valley of death,” which tends to hold up the deployment of these 
novel procedures in clinical practice [109–113].
ATMPs are regulated in the European Union by Directives 1394/2007 [114] and 
2009/120/EC [115], which amended Directive 2001/83/EC. Those products are con-
trolled by the Committee for Advanced Therapies and the Committee for Medicinal 
Products for Human Use of the European Medicines Agency (EMA), the European 
equivalent of the United States’ Food and Drug Administration (FDA). The drug 
regulatory agencies of Australia [116], Canada [117], the United States [118], Korea 
[119], Singapore [120] and Japan [121] have developed a specific framework for 
regulating their use [122].
Meeting the requirements for the accreditation, designation, authorization, or 
licensing of the tissue establishments and cell preparation processes involved in 
advanced therapy medicinal products can be challenging. As explained above, the 
main goal is to ensure that such processes are safe. However, it must be considered 
that regulatory agencies prefer to tread cautiously into this uncharted territory so 
full of legal loopholes. Apart from addressing those loopholes, which is the respon-
sibility of the legislative bodies, an attempt should be made at harmonizing the 
safety norms applicable to advanced therapy medicinal products across the different 
regulatory agencies, particularly concerning their general principles, which seem to 
be more skewed toward ensuring patient safety than facilitating the development of 
innovative therapies to address current medical challenges. This is of course com-
plicated by the fact that the handling and manipulation of cells and tissue materials 
must be performed under Good Manufacturing Practice (GMP) conditions as 
regulated by Directive 2003/94/EC [123].
It is therefore necessary to find a compromise between the three terms in the 
equation: safety, economic investments, and cost-efficiency. In severe or fatal 
conditions cost-efficiency tends to be very high but in others such as dental condi-
tions, which are typically non-fatal, there being other longer-standing and more 
economical alternatives cost-efficiency is usually much lower. A consensus must be 
reached between academia, industry, regulatory authorities, and other stakeholders 
that paves the way to improving the design of ATMPs, facilitating their use, and 
making it easier for them to make the transition from bench to bedside. In other 
words, regulation, reimbursement, and realization are the 3 Rs [124] required to 
ensure that patients can benefit from advanced therapies in a safe and efficient way.
It could be argued that the lack of correlation between novel ideas and therapeu-
tic procedures on the one hand, and clinical practice on the other, is generally due 
not so much to scientific reasons but rather to regulatory and cost-related ones. It 
must be considered that advanced therapies are essentially personalized rather than 
one-size-fits-all therapies, which inevitably leads to higher design and production 
costs [125].
It should not be forgotten that the rate of progress in a given clinical domain is 
determined by the importance assigned by governments and societies to advances 
in that domain. Indeed, implementation of novel technologies is heavily influenced 
by their usefulness in the eyes of society, particularly in the face of an ever-increas-
ing life expectancy, which inevitable leads to a rise in the number of comorbidities. 
From a dentistry perspective, dental problems resulting from a longer life expec-
tancy lead to a lower quality of life because of a disturbed masticatory function.
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Priorities in the realm of dentistry are also influenced by the idiosyncrasies and 
the mindsets of the different countries and geographical regions with respect to 
healthcare policy. In some Western countries, dental care and hygiene have been 
considered to play a secondary role, which has resulted in a lack of awareness of 
the importance of dental education and an ensuing lack of prevention programs. 
Some governments do not seem willing to devote the required resources to address 
conditions that might not appear excessively severe at first glance, but which result 
in significant direct and indirect social costs in the medium or long-term.
Implementation of new therapeutic strategies and procedures is clearly con-
strained by the level of priority given to specific clinical areas, starting at the base of 
the pyramid, which is prevention-oriented health education. In dentistry, as well as 
in other areas, it is essential to support research into new therapies based on ATMPs 
in order to provide patients with alternative dental treatments that are safer and 
more effective in the long term.
5. Conclusions
• The topic addressed in this chapter, i.e., the contribution of gene and cell 
therapy to dental tissue regeneration, is closely related to developmental dental 
defects and their treatment. Protocols based on gene and cell therapy repre-
sent “curative” rather than “palliative” therapeutic tools for defects affecting 
human dental hard tissues. Proteomics, genomics, and biomaterials science 
will be instrumental for translating these strategies into clinical practice.
• Advanced therapies constitute potentially essential strategies for the treatment 
of periodontal disease.
• Gene therapy, through adeno-associated or lentiviral vectors could activate 
periodontal tissue and alveolar bone modulation through the transfer of 
“therapeutic” genes expressing proteins such as BMPs, osteoprotegerin, or 
tissue- nonspecific alkaline phosphatase, which is deficient in patients with HPP 
(a condition that affects mineralization of teeth and bone) among others. Those 
genes could also express factors such as the platelet-derived growth factor.
• In cell therapy, mesenchymal stem cells implemented in an autologous, 
allogeneic or xenogeneic manner, with the aid of scaffolds to enable the 
required three-dimensional environment, have been shown by several clini-
cal trials to have a significant bone regeneration potential in the context of 
osteoporosis, osteonecrosis or alveolar bone regeneration (osseointegration) 
prior to placement of a dental implant. Use of these cells is safe as they do not 
present with teratogenicity, they have immunomodulating properties, and 
they do not pose the risk of immune rejection. The implanted cells maintain 
homeostasis across all periodontal tissues and are capable of preserving and 
regenerating the alveolar bone and the tooth and implant supporting struc-
tures by managing the balance between bone formation and bone resorption. 
The results obtained have thus far offered significant promise in terms of the 
long-term durability of implants given the efficacy observed in the induction 
of osseointegration.
• Implementation of the new therapies will require finding a compromise 
between safety, economic investments, and cost-efficiency. It will be neces-
sary to reach a consensus between academia, industry, and the regulatory 
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